INVEGA HAFYERA Drug Insight

“INVEGA HAFYERA Market Size, Forecast, and Drug Insight – 2032” report provides comprehensive insights about INVEGA HAFYERA for schizophrenia in the seven major markets. A detailed picture of the INVEGA HAFYERA for schizophrenia in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the INVEGA HAFYERA for schizophrenia. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the INVEGA HAFYERA market forecast analysis for schizophrenia in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in schizophrenia.

Drug Summary

INVEGA HAFYERA is twice yearly injections, which is atypical antipsychotics containing a racemic mixture of the active ingredient paliperidone. This active ingredient belongs to the chemical class of benzisoxazole derivatives. INVEGA HAFYERA is a long-acting injectable treatment administered in the upper buttocks area every 6 months. INVEGA HAFYERA dissolves slowly into the bloodstream after injection, resulting in continuous treatment and symptom control over 6 months.

Mechanism of action

Paliperidone palmitate is hydrolyzed to paliperidone. Paliperidone is the major active metabolite of risperidone. The mechanism of action of paliperidone is unclear. However, the drug’s therapeutic effect in schizophrenia could be mediated through a combination of central dopamine type 2 (D2) and serotonin type 2 (5HT2A) receptor antagonism.

Dosage

It is recommended to administer INVEGA HAFYERA by gluteal injection once every 6 months. Initiate INVEGA HAFYERA when the next once-a-month or every 3-month paliperidone palmitate extended-release injectable suspension dose is scheduled. The dose is based on the previous once-a-month or every 3-month product.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the INVEGA HAFYERA description, mechanism of action, dosage and administration, research and development activities in schizophrenia.
• Elaborated details on INVEGA HAFYERA regulatory milestones and other development activities have been provided in this report.
• The report also highlights the INVEGA HAFYERA research and development activities in schizophrenia across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around INVEGA HAFYERA.
• The report contains forecasted sales of for schizophrenia till 2032.
• Comprehensive coverage of the late-stage emerging therapies for schizophrenia.
• The report also features the SWOT analysis with analyst views for INVEGA HAFYERA in schizophrenia.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

INVEGA HAFYERA Analytical Perspective by DelveInsight

• In-depth INVEGA HAFYERA Market Assessment

This report provides a detailed market assessment of INVEGA HAFYERA for schizophrenia in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

• INVEGA HAFYERA Clinical Assessment

The report provides the clinical trials information of INVEGA HAFYERA for schizophrenia covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for schizophrenia is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence INVEGA HAFYERA dominance.
• Other emerging products for schizophrenia are expected to give tough market competition to INVEGA HAFYERA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of INVEGA HAFYERA in schizophrenia.
• Our in-depth analysis of the forecasted sales data of INVEGA HAFYERA from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the INVEGA HAFYERA in schizophrenia.

Key Questions

• What is the product type, route of administration and mechanism of action of INVEGA HAFYERA?
• What is the clinical trial status of the study related to INVEGA HAFYERA in schizophrenia and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the INVEGA HAFYERA development?
• What are the key designations that have been granted to INVEGA HAFYERA for schizophrenia?
• What is the forecasted market scenario of INVEGA HAFYERA for schizophrenia?
• What are the forecasted sales of INVEGA HAFYERA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available and how are these giving competition to INVEGA HAFYERA for schizophrenia?
• Which are the late-stage emerging therapies under development for the treatment of schizophrenia?